Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥8823.3B | ¥8750.3B | +0.8% |
| Operating Income | ¥700.6B | ¥664.5B | +5.4% |
| Ordinary Income | ¥724.0B | ¥650.4B | +11.3% |
| Net Income | ¥426.5B | ¥465.3B | −8.3% |
| ROE | 5.3% | 5.9% | - |
Executive Summary
The Company reported higher revenue and operating income, with the operating income growth rate exceeding the revenue growth rate; however, net income attributable to owners of the parent declined due to the recognition of extraordinary losses. Revenue was ¥8,823.3B (+0.8% YoY), operating income was ¥700.6B (+5.4%), and ordinary income was ¥724.0B (+11.3%). Meanwhile, net income attributable to owners of the parent was ¥388.2B (-11.0%), primarily because extraordinary losses of ¥120.7B, including impairment losses of ¥46.0B, exceeded extraordinary gains of ¥53.2B. The operating margin improved to 7.9% from 7.6% in the same period of the previous year, indicating that core business profitability remained solid.
Factors Affecting Business Performance
【Revenue】Revenue was ¥8,823.3B, representing a modest 0.8% increase YoY. By segment, the core Food Business recorded higher revenue of ¥7,111.4B (80.5% of total revenue, +1.3% YoY), while the Pharmaceutical Business posted lower revenue of ¥1,722.4B (19.5% of total revenue, -1.1% YoY). Growth in the Food Business supported the Company-wide top line.
【Profit and Loss】Operating income was ¥700.6B (+5.4% YoY), exceeding the 0.8% revenue growth rate, with operating leverage having a positive effect. By segment, Food increased significantly to ¥536.5B (+8.4%, 7.5% margin), while Pharmaceuticals secured higher profit of ¥205.5B (+1.1%, 11.9% margin) despite lower revenue. Ordinary income was ¥724.0B (+11.3%), with the improvement in non-operating income and expenses, including foreign exchange gains of ¥20.0B, providing an additional contribution. However, extraordinary losses of ¥120.7B (including impairment losses of ¥46.0B) exceeded extraordinary gains of ¥53.2B, resulting in profit before income taxes of ¥656.5B (-3.9% YoY). Consequently, net income attributable to owners of the parent declined to ¥388.2B (-11.0%), contrasting with the increase in ordinary income. In summary, the Company achieved higher revenue and profit at the operating and ordinary income levels, while final profit declined due to extraordinary income and expenses.
Segment Analysis
The Food Business recorded higher revenue and profit, with revenue of ¥7,111.4B (+1.3% YoY), segment profit of ¥536.5B (+8.4%), and a 7.5% margin, making it the main driver of consolidated profit growth. The Pharmaceutical Business posted lower revenue of ¥1,722.4B (-1.1% YoY), but maintained higher profitability than Food, with segment profit of ¥205.5B (+1.1%) and an 11.9% margin. Improvements in pricing and product mix appear to have contributed. Company-wide expenses, including holding company operating expenses, were ¥41.6B, up from ¥33.6B in the same period of the previous year, partially offsetting the profit growth effects of both segments. If the Pharmaceutical Business’s revenue decline continues, attention should be paid to the sustainability of improvements in the Company-wide profit margin.
Key Financial Metrics
【Profitability】The 7.9% operating margin improved from 7.6% in the same period of the previous year. With a gross profit margin of 30.5% and an SG&A expense ratio of 22.6%, the cost structure remained broadly stable. ROE was 5.3% (Company-disclosed figure). Based on a decomposition into a 4.8% net profit margin, 0.68x total asset turnover, and 1.61x financial leverage, the low asset turnover and net profit margin are constraints on ROE. 【Cash Flow Quality】Operating Cash Flow (OCF) was limited to ¥42.7B, and its ratio to net income attributable to owners of the parent of ¥388.2B was low at 0.11x. The primary reason was an outflow of working capital caused by increases of ¥440.8B in accounts receivable and ¥397.6B in inventories. 【Investment Efficiency】Capital expenditures of ¥672.5B reached 1.65x depreciation and amortization of ¥408.8B, indicating a phase of expansionary investment that includes ¥770.0B in construction in progress (5.9% of total assets). 【Financial Soundness】The financial base is strong, with an equity ratio of 62.0% and a current ratio of 168.3%. Interest-bearing debt was 0.71x EBITDA, while interest coverage was high, indicating that financial expenses were not placing pressure on earnings.
Cash Flow Analysis
OCF declined significantly to ¥42.7B from ¥239.3B in the same period of the previous year, resulting in negative free cash flow of ¥714.8B. Although operating cash flow before changes in working capital, including depreciation and amortization of ¥408.8B, totaled ¥300.8B, the accumulation of working capital—an increase of ¥440.8B in accounts receivable and ¥397.6B in inventories—far exceeded the cash inflow from the ¥146.8B increase in accounts payable, weighing on OCF. On the investment side, investing cash flow resulted in an outflow of ¥757.5B, primarily due to capital expenditures of ¥672.5B, meaning that OCF was insufficient to fund investment. This shortfall was covered by external financing, including a ¥652.2B inflow from financing cash flow, specifically the raising of ¥450.0B in long-term borrowings and the issuance of commercial paper. Overall, growth investment and the increase in working capital coincided during the period, resulting in a funding structure that did not rely on internally generated cash.
Earnings Quality
The increases in operating and ordinary income reflect an improvement in recurring earnings power derived from the business, while the decline in net income attributable to owners of the parent resulted from non-recurring extraordinary income and expenses; earnings quality therefore differs by earnings level. Foreign exchange gains of ¥20.0B were included in non-operating income of ¥48.0B, indicating that part of the increase in ordinary income depended on foreign exchange, a volatile factor. Extraordinary losses of ¥120.7B included impairment losses of ¥46.0B and exceeded extraordinary gains of ¥53.2B, including gains on sales of fixed assets of ¥19.1B, thereby reducing profit before income taxes and net income. From an accrual perspective—the gap between accrual-based earnings and cash earnings—OCF was significantly below net income, and earnings were accompanied by increases in accounts receivable and inventories. Accordingly, the extent to which earnings were converted into cash during the period was limited.
Earnings Forecast and Guidance
Progress toward the full-year Company forecast—revenue of ¥11,770.0B, operating income of ¥910.0B, ordinary income of ¥875.0B, and net income attributable to owners of the parent of ¥540.0B—was 75.0% for revenue, 77.0% for operating income, 82.7% for ordinary income, and 71.9% for net income. Progress for operating income and ordinary income exceeded revenue progress, indicating that the plan was not weighted toward Q4. The relatively high progress rate for ordinary income was attributable to the improvement in non-operating income and expenses, including foreign exchange gains; therefore, attention should be paid to the reproducibility of this contribution. The 71.9% progress rate for net income may fluctuate depending on the occurrence of extraordinary income and expenses.
Shareholder Returns
The full-year dividend forecast is ¥105.0 per share, while the Q2 dividend of ¥52.5 represents exactly half of the annual forecast. This indicates an upward trend from the previous year’s annual dividend (¥50 as of Q2). The forecast payout ratio calculated using forecast full-year net income of ¥540.0B is approximately 52.7%, a level below the general guideline for sustainability based on earnings. Meanwhile, cumulative free cash flow for the period was negative ¥714.8B, meaning that dividends could not be funded by cash flow during the period alone. Dividend sustainability is currently supported by financial capacity, including an equity ratio of 62.0% and low interest-bearing debt, while the extent of future recovery in OCF will remain an important focus.
Risk Factors
-
Prolonged working capital cycle: OCF was significantly below net income due to increases of ¥440.8B in accounts receivable and ¥397.6B in inventories, creating a divergence between earnings growth and cash generation. The timing of a recovery will be a key focus going forward.
-
Downside risk to final profit from extraordinary income and expenses: Extraordinary losses of ¥120.7B, including impairment losses of ¥46.0B, exceeded extraordinary gains of ¥53.2B, resulting in an 11.0% decline in net income attributable to owners of the parent despite higher operating income. Whether similar extraordinary income and expenses will occur again will be a key focus.
-
Growth disparity between segments: Revenue in the Pharmaceutical Business declined 1.1% YoY. Whether the segment can restore revenue growth while maintaining its high 11.9% margin will affect the sustainability of the Company-wide profit mix.
Industry Benchmark (Reference; Company Research)
Industry Benchmark (food_beverage)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 7.9% | 5.0% (4.5%–7.6%) | +2.9pt |
| Net Profit Margin | 4.8% | 3.9% (2.8%–6.7%) | +0.9pt |
The Company’s operating margin and net profit margin exceed the industry median, indicating relatively high profitability among its peers.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 0.8% | 3.4% (-0.4%–4.7%) | −2.6pt |
The Company’s revenue growth rate is below the industry median, indicating that top-line growth is less favorable than that of peers relative to its high profitability.
※Source: Company research
Key Points from the Earnings Results
-
Operating income increased 5.4% against a 0.8% increase in revenue, and the operating margin improved to 7.9%. While improvement in core business profitability is evident, the revenue growth rate is below the industry median, highlighting the balance between growth and profitability.
-
OCF was limited to ¥42.7B, representing a significant divergence from net income attributable to owners of the parent of ¥388.2B. The outflow of working capital caused by increases in accounts receivable and inventories was the primary factor, making the conversion of earnings into cash an ongoing point of focus.
-
Progress toward the full-year plan for operating income and ordinary income was 77.0% and 82.7%, respectively, exceeding revenue progress of 75.0%. From a profitability perspective, progress toward achieving the plan appears broadly on track.
Theoretical Stock Price (Reference Value)
| Scenario | Theoretical Stock Price |
|---|---|
| bear | ¥2,536 |
| base | ¥2,562 |
| bull | ¥2,642 |
| Calculation Assumption | Value |
|---|---|
| Book Value per Share (BPS) | ¥2,817 |
| Adjusted Forecast EPS | ¥168.1 |
| Cost of Equity r | 9.27% (10-year Japanese government bond 2.77% + equity risk premium 6.00% + size premium 0.50%) |
| Persistence Factor of Residual Income ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 53.1% |
| Forecast EPS Reliability Adjustment | ×0.850 (based on the Company’s historical track record of achieving guidance) |
| Implied PBR / PER | 0.91x / 15.2x |
Sensitivity: ¥2,492–¥2,635 at ±1% cost of equity, and ¥2,554–¥2,568 at ω±0.1.
Notes:
- Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
- Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market stock price or a recommendation of any specific investment action, and does not predict or guarantee future stock prices.)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and, as necessary, after consulting with a professional.
---End of Report---
AI Financial Analysis
Executive Summary
Meiji Holdings delivered a solid operating performance in FY2026 Q3, although bottom-line earnings and cash conversion weakened materially. Revenue increased 0.8% year on year to ¥882.3bn on a cumulative nine-month basis. Operating income rose faster, by 5.4% to ¥70.1bn, indicating a favorable profit mix and/or improved cost management despite limited top-line growth. The operating margin expanded by 30bp to 7.9% from 7.6% in the prior-year period. Gross profit increased 4.5% to ¥269.4bn, and the gross margin improved by 100bp to 30.5%, which is within the healthy 25-40% food-industry range. SG&A rose 4.2% to ¥199.4bn, modestly below gross-profit growth but well above revenue growth, so operating leverage depended on the gross-margin improvement rather than fixed-cost dilution. Ordinary income increased 11.3% to ¥72.4bn, aided by a ¥2.0bn foreign-exchange gain and lower non-operating expenses. Profit attributable to owners nevertheless declined 11.0% to ¥38.8bn. The principal reason was a deterioration below ordinary income: extraordinary losses totaled ¥12.1bn, including a ¥4.6bn impairment loss, versus ¥3.6bn in the prior-year period. The effective tax rate calculated from profit before tax and income tax expense was 35.0%, while the reported extended DuPont tax burden of 0.591 also signals a relatively high tax drag on the earnings measure used in that calculation. Operating cash flow was only ¥4.3bn, equivalent to 0.11x net income, which is the central weakness in the quarter. Receivables increased by ¥44.1bn and inventories by ¥39.8bn in the operating cash-flow bridge, absorbing cash despite a ¥14.7bn increase in trade payables. Heavy capital expenditure of ¥67.3bn, 1.65x depreciation and amortization, drove free cash flow to negative ¥71.5bn. The investment program was financed in part by ¥45.0bn of new long-term loans, contributing to financing cash inflow of ¥65.2bn. Liquidity and leverage remain sound, with a 168.3% current ratio, 0.61x debt-to-equity, 0.71x debt/EBITDA and 149.4x EBIT interest coverage. Full-year guidance implies Q3 cumulative progress of 75.0% for sales, 77.0% for operating income and 71.9% for profit attributable to owners. Accordingly, the operating-income outlook appears achievable, while full-year profit delivery requires a stronger Q4 and an absence of further exceptional charges. The principal forward-looking issue is whether receivables and inventory normalize sufficiently to restore cash conversion while the company continues its elevated manufacturing investment cycle.
Profitability Analysis
Annualized DuPont ROE is 6.4%, composed of a 4.4% net profit margin, 0.901x asset turnover and 1.61x financial leverage. The largest constraint is profitability rather than leverage: the 4.4% net margin and 6.4% annualized ROE remain below the cited 8% ROE threshold, while leverage is moderate and not being used aggressively. The operating margin improved 30bp year on year to 7.9%, supported by a 100bp increase in gross margin to 30.5%. This gross-margin improvement is particularly constructive for a food and beverage producer because it suggests that pricing, product mix, procurement actions, or manufacturing efficiency more than offset part of input-cost pressure. However, SG&A increased 4.2% versus revenue growth of 0.8%, limiting the conversion of gross-profit growth into operating-income growth. EBITDA was ¥110.9bn and the EBITDA margin was 12.6%, providing a stronger view of operating cash earning capacity before depreciation. The Q3 earnings profile was weakened by exceptional items: ¥12.1bn of extraordinary losses, including ¥4.6bn of impairment, exceeded ¥5.3bn of extraordinary income. This resulted in profit before tax declining 3.9% and profit attributable to owners declining 11.0%, notwithstanding higher operating and ordinary income. Interest burden remains benign at 0.937 and EBIT interest coverage is 149.4x, confirming that financing costs are not a meaningful drag on returns. The reported tax burden of 0.591 is below the 0.60 warning threshold and represents a material reduction from pre-tax earnings to the net-income measure used in the five-factor decomposition. Sustained improvement in ROE therefore depends mainly on retaining gross-margin gains, containing SG&A growth relative to revenue, avoiding repeat impairments, and improving utilization of the enlarged asset base.
Growth Assessment
Top-line growth was modest at 0.8%, but segment results show that the Food business was the main growth engine. Food external sales increased 1.3% to ¥710.1bn and segment profit increased 8.4% to ¥53.7bn. Pharmaceuticals external sales declined 1.1% to ¥172.2bn, while segment profit still increased 1.1% to ¥20.6bn. Food is the core business, contributing 72.3% of aggregate segment profit before corporate-cost allocation, compared with 27.7% from Pharmaceuticals. Food segment profit margin improved to 7.5% from 7.1%, while Pharmaceuticals maintained a much higher 11.9% margin despite its revenue decline. Aggregate segment profit rose 6.3% to ¥74.2bn, but unallocated corporate costs increased to ¥4.2bn from ¥3.4bn, reducing the group-level benefit. Full-year revenue guidance is ¥1,177.0bn, up 2.0% year on year, and Q3 progress is exactly 75.0%, consistent with a standard seasonal run-rate. Operating-income guidance is ¥91.0bn, up 7.4%, and Q3 progress of 77.0% is 2.0 percentage points ahead of the 75% reference level. Ordinary-income progress is 82.7% against ¥87.5bn guidance, which is ahead of the standard run-rate but includes non-operating foreign-exchange gains. Profit attributable to owners progress is 71.9% against ¥54.0bn guidance, 3.1 percentage points below the standard run-rate, reflecting the exceptional-loss burden. Growth quality is therefore mixed: operating profit is improving, but revenue growth is subdued, Pharmaceuticals sales are contracting, and net income is exposed to below-the-line volatility. The 2/10 consistency score also argues for caution in extrapolating the current margin improvement without confirmation in Q4.
Financial Health
The balance sheet remains financially resilient. Current assets of ¥615.5bn exceed current liabilities of ¥365.8bn, producing working capital of ¥249.7bn and a healthy current ratio of 168.3%. The quick ratio is also strong at 130.4%, indicating that liquidity does not depend solely on inventory realization. Cash and deposits of ¥78.9bn cover short-term loans of ¥22.6bn by 3.50x, limiting near-term refinancing pressure. Interest-bearing debt totals ¥79.1bn, equal to 0.61x equity, 0.71x EBITDA and 8.9% of capital; these are conservative solvency measures. Debt maturity risk is contained because the short-term debt ratio is 28.5%, while current assets are ample relative to short-term obligations. Long-term loans increased sharply by ¥44.1bn, or 355.3% year on year, to ¥56.6bn. This appears linked to funding a substantially higher investment program, rather than a stressed liquidity position, as the company generated ¥45.0bn of proceeds from long-term loans during the period. Nevertheless, this change should be monitored because operating cash flow did not fund the capital-expenditure program. Total assets expanded to ¥1,305.8bn, with PPE representing 40.2% of assets, consistent with a manufacturing-intensive operating model. Construction in progress increased to ¥77.0bn from ¥45.8bn, supporting the view that the company is in an active capacity-investment phase. Net defined benefit liabilities of ¥52.1bn are a relevant long-duration obligation, although they are manageable relative to owners' equity of ¥763.6bn. Intangible assets represent only 1.7% of total assets, and no material goodwill movement was reported, limiting M&A-related balance-sheet dependence. No current-ratio or debt-to-equity warning is triggered.
Notable B/S Changes
Long-term loans: +¥44.1bn (+355.3%) to ¥56.6bn - borrowing increased materially, consistent with financing elevated capital investment; monitor leverage and cash-return generation from the projects. PPE: +¥40.7bn (+8.4%) to ¥524.6bn - the manufacturing asset base is expanding, while construction in progress rose to ¥77.0bn from ¥45.8bn, indicating an active capacity-investment cycle. Trade receivables: +¥46.9bn (+24.7%) to ¥236.4bn - close to the material-change threshold and consistent with the 73-day DSO alert; this was a major operating-cash-flow outflow. Finished goods: +¥11.0bn (+8.6%) to ¥138.6bn, while raw materials increased to ¥108.8bn from ¥81.9bn - inventory build-up heightens commodity, obsolescence, and cash-conversion risk. Total liabilities: +¥103.7bn (+26.4%) to ¥496.4bn - liabilities increased faster than equity, primarily alongside the investment and funding cycle, though leverage remains conservative.
Cash Flow Quality
Cash-flow quality is weak in FY2026 Q3 and requires close monitoring. Operating cash flow was ¥4.3bn against ¥38.8bn of profit attributable to owners, resulting in an OCF/net-income ratio of 0.11x, well below the 0.8x quality threshold. Cash conversion, measured as OCF/EBITDA, was only 0.04x, also far below the 0.7x alert threshold. The main driver was working-capital absorption: trade receivables increased by ¥44.1bn and inventories increased by ¥39.8bn in the cumulative cash-flow statement. Higher trade payables of ¥14.7bn partly offset this absorption but were insufficient to protect operating cash generation. Quality alerts also identify receivable days of 73 days, above the 60-day threshold, and a 134-day cash conversion cycle, above the 120-day threshold. These indicators raise the risk that cash collection and working-capital discipline are lagging reported revenue and earnings. Inventory-duration alerts are elevated, with reported indicators of 115 days and 62 days, both above their respective 90-day and 60-day alert thresholds; this is important for food products because slower stock rotation can increase obsolescence, markdown, and food-quality risk. The accruals ratio of 2.6% remains below the 5% benchmark, which is a mitigating factor and suggests the issue is principally working-capital timing rather than broadly excessive accounting accruals. Capex of ¥67.3bn exceeded depreciation and amortization of ¥40.9bn by 65%, implying expansionary investment rather than maintenance-only spending. Free cash flow was negative ¥71.5bn, and investing cash outflow totaled ¥75.7bn. Financing cash inflow of ¥65.2bn, led by new long-term borrowing, largely funded the gap. Restoration of OCF through collection of receivables and normalization of inventories is necessary for the current investment rate to be sustainably self-funded.
Dividend Sustainability
The indicated full-year dividend is ¥105.0 per share, comprising the ¥52.5 interim dividend and an implied ¥52.5 year-end dividend. Against forecast EPS of ¥197.8, the forecast dividend payout ratio is approximately 53.1%, within the stated sub-60% sustainability benchmark. The interim dividend of ¥52.5 is also above the prior-year ¥50.0 per share level. On an accrual earnings basis, the dividend framework appears supportable by forecast profit attributable to owners of ¥54.0bn. However, free cash flow was negative ¥71.5bn in the Q3 cumulative period and reported FCF coverage was negative 4.82x. Accordingly, dividend funding during this investment phase depends on cash balances, future operating-cash recovery, and financing capacity rather than internally generated free cash flow alone. Balance-sheet capacity is currently sufficient, given low debt/EBITDA and strong interest coverage. The key determinant of dividend sustainability is therefore not leverage today, but whether receivable and inventory cash absorption reverses while high capex continues. No total return ratio is calculated because the available data do not indicate a material share-buyback program in the current period.
Risk Assessment
Business risks include Working-capital execution risk: receivable days of 73 and a 134-day cash conversion cycle indicate slower cash realization from sales., Inventory-management and food-industry risk: elevated inventory-day indicators of 115 days and 62 days increase exposure to obsolescence, write-downs, freshness management, and demand-forecasting errors., Input-cost and pricing risk: the Food business carries substantial exposure to agricultural commodities, dairy, cocoa, sugar, packaging, energy, and foreign-exchange movements; continued gross-margin improvement depends on pricing power and procurement discipline., Pharmaceutical revenue risk: Pharmaceuticals sales declined 1.1% year on year, despite a small profit increase, creating a risk that mix, volumes, or product-cycle pressures limit group growth., Impairment and asset-utilization risk: the ¥4.6bn impairment loss and a growing manufacturing asset base require evidence that investment projects achieve expected utilization and returns., Food safety, product recall, labeling, and consumer-preference risks remain material industry-specific exposures for branded food and beverage operations..
Financial risks include Earnings-quality risk is high in the current period: OCF/net income was 0.11x and OCF/EBITDA was 0.04x, indicating that accounting earnings were not converted into cash., Free-cash-flow deficit risk: negative ¥71.5bn FCF resulted from ¥67.3bn of capex and weak OCF, increasing reliance on external financing during the investment cycle., Debt has increased through a ¥44.1bn year-on-year rise in long-term loans; leverage remains low, but further debt-funded capex without OCF recovery would weaken financial flexibility., Tax drag risk: the reported five-factor tax burden of 0.591 is below the 0.60 warning threshold and reduces the translation of pre-tax profit into net income..
Key concerns include Highest priority: whether the ¥44.1bn receivables increase and ¥39.8bn inventory increase reverse in Q4, allowing operating cash flow to converge toward earnings., High priority: whether gross-margin expansion can offset SG&A growth that is currently outpacing revenue growth., Medium priority: whether the company can meet full-year profit attributable to owners guidance after Q3 progress of 71.9%, below the standard 75% progress level., Medium priority: the pace and return profile of capex, which is running at 1.65x depreciation and is being partly financed by new long-term loans., Medium priority: recurrence of extraordinary losses, particularly impairment, which caused net income to decline despite improved operating income..
Investment Implications
Key takeaways include Operating fundamentals improved: operating income rose 5.4% and the operating margin expanded 30bp to 7.9% despite revenue growth of only 0.8%., Food is the core profit contributor and delivered stronger sales and margin performance, while Pharmaceuticals preserved a superior margin but experienced lower sales., The decline in profit attributable to owners was driven by exceptional losses, including ¥4.6bn of impairment, rather than deterioration in operating income., Liquidity and debt-service capacity are strong, but negative free cash flow and debt-funded investment make working-capital normalization critical., Forecast operating-income progress is ahead of a standard Q3 run-rate, whereas profit attributable to owners progress is modestly behind it..
Metrics to watch include Operating cash flow, OCF/net income, and OCF/EBITDA cash conversion, Trade receivables, DSO, inventories, inventory days, and cash conversion cycle, Food segment revenue growth and segment margin, Pharmaceutical segment sales trajectory and margin resilience, Capex, construction in progress, capex/depreciation, and long-term loan balances, Further impairment charges, extraordinary gains/losses, and the effective tax burden, Q4 progress toward ¥91.0bn operating-income and ¥54.0bn profit-attributable guidance.
Regarding relative positioning, Meiji exhibits a defensively financed, brand-led food and pharmaceutical profile with healthy gross margin and strong interest coverage. Its 30.5% gross margin is within the healthy food-industry range and its 12.6% EBITDA margin supports underlying profitability. Relative weaknesses are a sub-8% annualized ROE, modest revenue growth, and unusually poor current-period cash conversion caused by working-capital absorption and elevated investment spending.